Free Trial
→ Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th... (From Banyan Hill Publishing) (Ad)tc pixel Free TERN Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Terns Pharmaceuticals (TERN) Competitors

Terns Pharmaceuticals logo
Compare

TERN vs. INSM, BNTX, ROIV, VTRS, and MRNA

Should you buy Terns Pharmaceuticals stock or one of its competitors? MarketBeat compares Terns Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Terns Pharmaceuticals include Insmed (INSM), BioNTech (BNTX), Roivant Sciences (ROIV), Viatris (VTRS), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.

How does Terns Pharmaceuticals compare to Insmed?

Insmed (NASDAQ:INSM) and Terns Pharmaceuticals (NASDAQ:TERN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Terns Pharmaceuticals has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Terns Pharmaceuticals' return on equity of -20.02% beat Insmed's return on equity.

Company Net Margins Return on Equity Return on Assets
Insmed-144.44% -130.11% -51.57%
Terns Pharmaceuticals N/A -20.02%-19.37%

Insmed has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, Terns Pharmaceuticals has a beta of -0.37, suggesting that its share price is 137% less volatile than the broader market.

98.3% of Terns Pharmaceuticals shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Comparatively, 1.5% of Terns Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Terns Pharmaceuticals has lower revenue, but higher earnings than Insmed. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insmed$606.42M37.97-$1.28B-$5.75N/A
Terns PharmaceuticalsN/AN/A-$96.21M-$1.03N/A

In the previous week, Insmed had 20 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 20 mentions for Insmed and 0 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 1.35 beat Insmed's score of 1.08 indicating that Terns Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Insmed Positive
Terns Pharmaceuticals Positive

Insmed presently has a consensus target price of $210.95, indicating a potential upside of 98.56%. Terns Pharmaceuticals has a consensus target price of $55.14, indicating a potential upside of 4.13%. Given Insmed's stronger consensus rating and higher probable upside, equities research analysts clearly believe Insmed is more favorable than Terns Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Insmed
1 Sell rating(s)
0 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.96
Terns Pharmaceuticals
1 Sell rating(s)
10 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.27

Summary

Insmed beats Terns Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Terns Pharmaceuticals compare to BioNTech?

Terns Pharmaceuticals (NASDAQ:TERN) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

98.3% of Terns Pharmaceuticals shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 1.5% of Terns Pharmaceuticals shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, BioNTech had 7 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 7 mentions for BioNTech and 0 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 1.35 beat BioNTech's score of 0.79 indicating that Terns Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Terns Pharmaceuticals Positive
BioNTech Positive

Terns Pharmaceuticals has higher earnings, but lower revenue than BioNTech. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Terns PharmaceuticalsN/AN/A-$96.21M-$1.03N/A
BioNTech$3.25B7.18-$1.29B-$5.88N/A

Terns Pharmaceuticals has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Terns Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Terns PharmaceuticalsN/A -20.02% -19.37%
BioNTech -44.39%-5.30%-4.62%

Terns Pharmaceuticals has a beta of -0.37, meaning that its stock price is 137% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market.

Terns Pharmaceuticals presently has a consensus price target of $55.14, suggesting a potential upside of 4.13%. BioNTech has a consensus price target of $128.44, suggesting a potential upside of 39.39%. Given BioNTech's stronger consensus rating and higher possible upside, analysts clearly believe BioNTech is more favorable than Terns Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Terns Pharmaceuticals
1 Sell rating(s)
10 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.27
BioNTech
1 Sell rating(s)
5 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.68

Summary

BioNTech beats Terns Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Terns Pharmaceuticals compare to Roivant Sciences?

Terns Pharmaceuticals (NASDAQ:TERN) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Terns Pharmaceuticals presently has a consensus target price of $55.14, indicating a potential upside of 4.13%. Roivant Sciences has a consensus target price of $33.05, indicating a potential upside of 10.30%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Roivant Sciences is more favorable than Terns Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Terns Pharmaceuticals
1 Sell rating(s)
10 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.27
Roivant Sciences
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75

Terns Pharmaceuticals has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Terns Pharmaceuticals' return on equity of -20.02% beat Roivant Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Terns PharmaceuticalsN/A -20.02% -19.37%
Roivant Sciences -3,629.19%-20.54%-19.43%

In the previous week, Roivant Sciences had 27 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 27 mentions for Roivant Sciences and 0 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 1.35 beat Roivant Sciences' score of 0.43 indicating that Terns Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Terns Pharmaceuticals Positive
Roivant Sciences Neutral

Terns Pharmaceuticals has higher earnings, but lower revenue than Roivant Sciences. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Terns PharmaceuticalsN/AN/A-$96.21M-$1.03N/A
Roivant Sciences$8.26M2,595.93-$171.98M-$0.60N/A

Terns Pharmaceuticals has a beta of -0.37, indicating that its stock price is 137% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market.

98.3% of Terns Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 1.5% of Terns Pharmaceuticals shares are owned by company insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Roivant Sciences beats Terns Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Terns Pharmaceuticals compare to Viatris?

Viatris (NASDAQ:VTRS) and Terns Pharmaceuticals (NASDAQ:TERN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

Terns Pharmaceuticals has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Terns Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viatris$14.30B1.36-$3.51B-$0.26N/A
Terns PharmaceuticalsN/AN/A-$96.21M-$1.03N/A

79.9% of Viatris shares are held by institutional investors. Comparatively, 98.3% of Terns Pharmaceuticals shares are held by institutional investors. 0.3% of Viatris shares are held by company insiders. Comparatively, 1.5% of Terns Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Terns Pharmaceuticals has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Terns Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Viatris-2.04% 19.04% 7.62%
Terns Pharmaceuticals N/A -20.02%-19.37%

Viatris has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Terns Pharmaceuticals has a beta of -0.37, suggesting that its share price is 137% less volatile than the broader market.

In the previous week, Viatris had 3 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 3 mentions for Viatris and 0 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 1.35 beat Viatris' score of 0.15 indicating that Terns Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Viatris Neutral
Terns Pharmaceuticals Positive

Viatris currently has a consensus target price of $16.43, suggesting a potential downside of 1.33%. Terns Pharmaceuticals has a consensus target price of $55.14, suggesting a potential upside of 4.13%. Given Terns Pharmaceuticals' higher probable upside, analysts plainly believe Terns Pharmaceuticals is more favorable than Viatris.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viatris
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.38
Terns Pharmaceuticals
1 Sell rating(s)
10 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.27

Summary

Viatris and Terns Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Terns Pharmaceuticals compare to Moderna?

Terns Pharmaceuticals (NASDAQ:TERN) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Terns Pharmaceuticals currently has a consensus target price of $55.14, suggesting a potential upside of 4.13%. Moderna has a consensus target price of $35.73, suggesting a potential downside of 23.78%. Given Terns Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Terns Pharmaceuticals is more favorable than Moderna.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Terns Pharmaceuticals
1 Sell rating(s)
10 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.27
Moderna
5 Sell rating(s)
12 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
1.84

Terns Pharmaceuticals has higher earnings, but lower revenue than Moderna. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Terns PharmaceuticalsN/AN/A-$96.21M-$1.03N/A
Moderna$1.94B9.57-$2.82B-$8.15N/A

In the previous week, Moderna had 16 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 16 mentions for Moderna and 0 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 1.35 beat Moderna's score of -0.20 indicating that Terns Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Terns Pharmaceuticals Positive
Moderna Neutral

Terns Pharmaceuticals has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Terns Pharmaceuticals' return on equity of -20.02% beat Moderna's return on equity.

Company Net Margins Return on Equity Return on Assets
Terns PharmaceuticalsN/A -20.02% -19.37%
Moderna -143.55%-26.64%-19.32%

Terns Pharmaceuticals has a beta of -0.37, suggesting that its share price is 137% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

98.3% of Terns Pharmaceuticals shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 1.5% of Terns Pharmaceuticals shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Terns Pharmaceuticals beats Moderna on 10 of the 16 factors compared between the two stocks.

Get Terns Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TERN vs. The Competition

Export
MetricTerns PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$6.12B$3.37B$6.46B$12.34B
Dividend YieldN/A2.26%2.76%5.28%
P/E Ratio-51.4118.7421.2125.65
Price / SalesN/A323.98554.3886.31
Price / CashN/A125.1743.4956.67
Price / Book5.467.0910.377.14
Net Income-$96.21M$24.45M$3.57B$335.98M

Terns Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TERN
Terns Pharmaceuticals
1.5999 of 5 stars		$52.95
flat		$55.14
+4.1%		+1,653.3%$6.12BN/AN/A40
INSM
Insmed
3.4941 of 5 stars		$108.14
+0.9%		$210.95
+95.1%		+57.3%$23.41B$819.56MN/A1,664
BNTX
BioNTech
3.7761 of 5 stars		$88.16
-0.8%		$130.60
+48.1%		-6.6%$22.28B$3.25BN/A7,807
ROIV
Roivant Sciences
2.2994 of 5 stars		$28.17
-1.3%		$30.55
+8.5%		+175.6%$20.12B$13.31MN/A860
VTRS
Viatris
2.2317 of 5 stars		$16.14
-2.2%		$16.43
+1.8%		+100.8%$18.79B$14.30BN/A30,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TERN) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Gold surged 600 dollars last time this indicator peaked
The Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...
Porter & Company | Sponsoredtc pixel
Opportunity Forming in a U.S. Supply-Chain Weak Spot?
America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...
i2i Marketing Group, LLC | Sponsoredtc pixel